Scientists hunt for new treatments for liver metastases in colorectal and pancreatic cancers
NCT ID NCT04622423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to understand why liver metastases are so deadly in colorectal and pancreatic cancers. Researchers will analyze tumors and blood from 625 participants to find new targets for immune and gene therapies. The goal is to develop better treatments for these hard-to-treat cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 625 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2019
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
CRC and PDAC patients with hepatic MTS, primary non-metastatic PDAC patients, IMPN patients, and healthy volunteers. Eligible patients, chosen among those who receive health care assistance/treatment for their disease at IRCCS San Raffaele, will be asked to signing of the predisposed informed consent form in case they decide to participate in this study.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion and exclusion criteria - CRC patients Inclusion criteria: 1. Patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver (stage IV disease, AJCC) 2. Patients with indication to surgical resection and/or chemotherapy treatment 3. Age ≥18 4. ECOG PS 0-1 at enrollment 5. Written informed consent 6. Patients will be treated in IRCCS San Raffaele Exclusion criteria: 1. Pregnancy or lactation 2. Inability to provide a written informed consent 3. Extraepatic disease with the exception of selected cases in which the coexistence of extrahepatic disease does not constitute an exclusion criterion for hepatic resective surgery (for example in patients with extraepatic lesions in remission or in any case stabilized by chemotherapy) 4. Severe comorbidities (e.g. cardiac diseases, history of psychiatric disabilities, HIV, autoimmune disorders) 5. Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy 6. Other conditions (medical or psychiatric) that in the judgment of Investigators would make the patient an inappropriate candidate for the study Inclusion and exclusion criteria - PDAC patients Inclusion criteria: 1. Patients with clinical/radiological diagnosis/suspicious of pancreatic adenocarcinoma metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) 2. Age ≥18 3. Karnofsky performance status ≥50 4. Metastatic pancreatic adenocarcinoma patients with histological specimens from whole liver metastasis biopsy or core liver biopsy collected at IRCCS San Raffaele and stored in the institutional biobank Centro Risorse Biologiche (CRB-OSR) 5. Written Informed consent 6. Patients with clinical/radiological diagnosis of not metastatic primary PDAC that will undergo pancreatic resection at IRCCS San Raffaele Exclusion criteria: 1. Severe comorbidities (e.g., cardiac diseases, history of psychiatric disabilities) representing an absolute contraindication for whole or core liver metastasis biopsy 2. Pregnancy or lactation 3. Inability to provide a written informed consent 4. Metastatic pancreatic adenocarcinoma patients enrolled in other research trials entailing the analysis of the liver metastasis histological sample
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer (CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS San Raffaele
RECRUITINGMilan, Milan, 26431, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple attack on pancreatic tumors: can radiation and immunotherapy make inoperable cancer operable?
- Old antiparasitic drug joins chemo in pancreatic cancer fight
- Alpha radiation targets tumors in new cancer trial
- Can Self-Compassion training break the isolation of life with a stoma?
- Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
- AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?